Literature DB >> 31811945

Is height important for quality of life in children with skeletal dysplasias?

Hortense Lorne1, Christopher J Newman2, Sheila Unger3.   

Abstract

Skeletal dysplasias are a large and heterogeneous group of conditions that affect growth and development of the skeleton. As might be expected, short stature is a frequent manifestation of these disorders but other complications do occur with varying frequencies depending on specific diagnosis and age of the patient. With the ongoing development of targeted therapies for achondroplasia and possibly other skeletal dysplasias, it is important to ascertain what are the factors influencing quality of life if we are to make meaningful assessments of therapeutic efficacy. Is it the short stature, in and of itself, that affects the quality of life for children with skeletal dysplasias or are the other complications more important determinants? We sought to address the effect of height by the use of questionnaire designed specifically for short stature; QoLissy. This questionnaire has been validated for use in Europe across several languages. Our study included 8 families with children between 8 and 18 years with a variety of skeletal dysplasia diagnoses. The results indicate a relatively low health-related quality of life from the child and parents' perspective, good coping strategies and, interestingly, a difference in perception of quality of life between parents and children, with parents rating the quality of life lower than their children. These results highlight the need for a more careful dissection of quality of life-influencers before deciding on how to assess drug efficacy and before advocating for multi-year therapy in children.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Achondroplasia; Quality of life; Short stature; Skeletal dysplasia

Mesh:

Year:  2019        PMID: 31811945     DOI: 10.1016/j.ejmg.2019.103816

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  2 in total

1.  Towards an ICF-based self-report questionnaire for people with skeletal dysplasia to study health, functioning, disability and accessibility.

Authors:  Heidi Anttila; Susanna Tallqvist; Minna Muñoz; Sanna Leppäjoki-Tiistola; Outi Mäkitie; Sinikka Hiekkala
Journal:  Orphanet J Rare Dis       Date:  2021-05-22       Impact factor: 4.123

2.  Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies.

Authors:  Ravi Savarirayan; Josep Maria De Bergua; Paul Arundel; Helen McDevitt; Valerie Cormier-Daire; Vrinda Saraff; Mars Skae; Borja Delgado; Antonio Leiva-Gea; Fernando Santos-Simarro; Jean Pierre Salles; Marc Nicolino; Massimiliano Rossi; Peter Kannu; Michael B Bober; John Phillips; Howard Saal; Paul Harmatz; Christine Burren; Garrett Gotway; Terry Cho; Elena Muslimova; Richard Weng; Daniela Rogoff; Julie Hoover-Fong; Melita Irving
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-03-21       Impact factor: 5.346

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.